Don’t let it disappear: new opportunities to prolong the life of HR+ HER2- advanced breast cancer patients. Event review of the satellite symposium. RUSSCO Big Conference «Breast Cancer» (online). January 28th, 2021

Increasing life expectancy and maintaining its quality are the main goals of the hormone-dependent HER2-negative advanced breast cancer (HR+ HER2- аBC) therapy. A Satellite Symposium of Novartis Pharma was held on January 28th, 2021, within the framework of the RUSSCO Big Conference Breast Cancer. I...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Editorial Board
Formato: article
Lenguaje:RU
Publicado: IP Habib O.N. 2021
Materias:
Acceso en línea:https://doaj.org/article/47732b8b0d2841bead79d5d3f5037738
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!